American Journal of Therapeutics · 2014 · 14 citations · 19 references
MedicineOncologyPharmacotherapyCancer Drug Toxicity ManagementMetastasisRenal PharmacotherapyKidney CancerRenal Cell CarcinomaRenal ToxicityAcute Adverse EventsHypothyroidism In Kidney DiseaseMental Status ChangesMetabolic EncephalopathyMetastatic Renal Cell Carcinoma TherapyNeurologic DeficitsSerious Adverse EventsThyroid-stimulating Hormone Testing
Sunitinib has become a standard treatment agent for metastatic renal cell carcinoma (RCC) for several years. However, various adverse events have been reported. We present a rare adverse effect of hyperammonemic encephalopathy induced by sunitinib. A 66-year-old woman with metastatic RCC referred to the emergency department with confusion that developed 14 days after the initiation of 50 mg/d of sunitinib. Her serum ammonia and thyroid-stimulating hormone levels were markedly elevated (146 μg/dL and 27.27 μIU/mL, respectively). Sunitinib was discontinued, and an enema with lactulose and L-thyroxine were administered. Her mental status and neurologic symptoms were normalized 7 days after the treatment. Serum ammonia level decreased to 61 μg/dL and thyroid stimulating hormone level decreased 22.34 μIU/mL. The incidence of sunitinib-induced hyperammonemia is rarely reported. The relationship between sunitinib and the development of hyperammonemia is not well understood, and the mechanism is unclear. Sunitinib-induced hyperammonemia is very rare, and to the best of our knowledge, this is fourth case hyperammonemia and first case hyperammonemic encephalopathy with hypothyroidism as an adverse effect. Therefore, it is important for clinicians to be aware of hyperammonemia that can occur in several days after the initiation of sunitinib treatment in metastatic RCC.
19
Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations
Medicine, Oncology, Pharmacology +15
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen et al. · Blood · 2003 · 857 citations · Full text
Medicine, Oncology, Pharmacology +11
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin Gore, Cezary Szczylik, Camillo Porta et al. · The Lancet Oncology · 2009 · 591 citations
Medicine, Oncology, Pharmacology +13
Resection of metastatic renal cell carcinoma.
Jeffrey P. Kavolius, Dimitrios P. Mastorakos, Christian P. Pavlovich et al. · Journal of Clinical Oncology · 1998 · 564 citations